Cryptocurrencies against cancer – Information

Can the cryptocurrencies help find a solution against cancer? Well, it is, although many may find it incredible. More and more businesses are seeking financing through a Token Generation Event (TGE)becoming a common practice in the crypto space.

KeyZell is the first biotech to perform a Token Generation Event (TGE) through the project K2Z Utility Tokenwhose maximum issuance will be 2,000 million tokens and 200,000 NFTs.

This innovative project intends to issue a useful fungible token to receive the service of its system of Artificial intelligence for precision medicineand another non-fungible token of the industrial property of this AI, baptized by KeyZell as IP-NFT (Industrial Property-NFT).

This issuance of tokens will allow them to continue advancing in their project of fight against cancer and operate in a safe environment, since they work under blockchain technology.

Global disease situation

The search for a cure for cancer has become one of the most lucrative businesses on the planet, far superior to technology. Everything is counted by thousands and millions in the fight against cancer. According to the latest study published by the IQVIA Institute, Global Oncology Trends 2021, it is estimated that the global market for treatments for this disease will reach 269 billion dollars by the year 2025. It is led by the USA with 42%, followed by the five main European markets: Germany, France, Great Britain, Italy and spain.

In 2020, almost 10 million people died from cancer and each year more than 19 million new cases are added worldwide. Unfortunately, every year the death forecasts are exceeded and incidence of the International Agency for Research on Cancer and, with these data, it is not surprising that in a short time one in three men and one in four women will be diagnosed with this disease throughout their lives.

Read also  graduality, diet, vitamin D and hydration

In addition, the global incidence is increasing due to the population aging and by the increase in risk factors.

TGE at the service of the fight against cancer

KeyZell’s K2Z Utility Token project is a model supported by the democratization of your industrial property in NFT format, and a company supported by a management and research team of international relevance. This project aims to make itself known among patients and be the way to really reach those who need it and not use it as a mere speculative investment.

NFTs are configured to generate or create payments on any future transfer of the tokens. This type of payment will be automated through a smart contract within the NFT, where the issuer can track the following transfers (resales), appearing registered in the blockchain where the NFT is made.

“KeyZell’s objective with the token is to bring a diagnostic service of personalized treatment against precision medicine cancer and that patients can get with NFTs new tokens every year to use them with AI. With this, we want to continue developing our KeyZell OPS project, a tool based on Machine Learning that selects the best treatment for each patient based on their individual characteristics,” says Jose de CorralCEO de KeyZell.

The company, pending to start with human clinical trials for the treatment of breast and lung cancerhas an innovative Artificial Intelligence system in the commercialization phase, a guarantee for the future to generate cashflow, and, above all, a guarantee for those investors looking for first-rate projects such as K2Z Token.

Read also  Men and Women, the tragedy and illness of Chiara Rabbi: "Because I was always swollen"

The company

KeyZell is formed by a multidisciplinary group of professionals from various fields, researchers from recognized centers of high prestige such as the University of Seville, the University of Malaga or the Imperial College of London, engineers with management experience in large international projects and senior professionals from the pharmaceutical, legal and business sectors.

The company is also backed by a highly qualified team of advisersnot only in the medical or scientific area, but also in intellectual property, legal or strategic issues.

Currently, KeyZell works on various lines of researchon the one hand, a new first-line treatment against some types of tumors, pending the start of phase I/IIa clinical trials, a pre-clinical phase treatment for prevent metastasis.

On the other hand, it develops the innovative artificial intelligence system KEYZELL OPS, of which it already has its industry licenseand which aims to be the future of precision medicine in oncology, and which is based on the search for patterns and personalized treatments for those cancer patients who do not respond to treatment, offering the most appropriate treatment for cancerin the convenient order and at the most appropriate time according to the characteristics of each patient.